"Acinus"
Welcome,         Profile    Billing    Logout  
 0 Trials 
11 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Yurkiv, Tetiana
NCT04469686 / 2019-003596-19: Phase 3 Study to Evaluate the Safety and Efficacy of Hydrocortisone Acetate Suppositories

Recruiting
3
618
Europe, US, RoW
Twice daily 90 mg hydrocortisone acetate suppository administered with Sephure applicator, Twice Daily - Active, Once daily 90 mg hydrocortisone acetate or placebo suppository administered with Sephure applicator, Once Daily - Active, Twice daily placebo suppository administered with Sephure applicator, Twice Daily - Placebo
Cristcot LLC, Cristcot HCA LLC
Ulcerative Proctitis
12/21
12/21
RESERVOIR, NCT04858425: Safety and Efficacy of Niclosamide in Patients With COVID-19 With Gastrointestinal Infection

Recruiting
2
159
US, RoW
Niclosamide, Placebo
AzurRx BioPharma, Inc.
Covid19
12/21
03/22
Ursol, Grygorii
NCT04469686 / 2019-003596-19: Phase 3 Study to Evaluate the Safety and Efficacy of Hydrocortisone Acetate Suppositories

Recruiting
3
618
Europe, US, RoW
Twice daily 90 mg hydrocortisone acetate suppository administered with Sephure applicator, Twice Daily - Active, Once daily 90 mg hydrocortisone acetate or placebo suppository administered with Sephure applicator, Once Daily - Active, Twice daily placebo suppository administered with Sephure applicator, Twice Daily - Placebo
Cristcot LLC, Cristcot HCA LLC
Ulcerative Proctitis
12/21
12/21
NCT04129502 / 2019-001845-42: TAK-788 as First-line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations

Checkmark [VIRTUAL] Mobocertinib (TAK-788) as first-line treatment vs platinum-based chemotherapy (CT) for NSCLC with EGFR exon 20 insertions (exon20ins)
Recruiting
3
318
Europe, Canada, US, RoW
TAK-788, AP32788, Pemetrexed, Alimta, Cisplatin, Carboplatin
Millennium Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited
Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)
06/22
11/24
LIBRETTO-431, NCT04194944 / 2019-001979-36: A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

Checkmark Phase III study of selpercatinib vs chemotherapy +/- pembrolizumab in untreated RET positive non-small-cell lung cancer.
Checkmark [VIRTUAL] LIBRETTO-431: Selpercatinib in Treatment-Naïve Patients with RET Fusion-Positive Non-Small Cell Lung Cancer (NSCLC).
Checkmark [VIRTUAL] LIBRETTO-431: Selpercatinib in treatment (Tx)-naïve patients with RET fusion-positive (RET+) non-small cell lung cancer (NSCLC)
Recruiting
3
250
Europe, Canada, Japan, RoW
Selpercatinib, LY3527723, LOXO-292, Carboplatin, Cisplatin, Pemetrexed, Pembrolizumab
Loxo Oncology, Inc., Eli Lilly and Company
Non-Small Cell Lung Cancer
01/23
08/25
SELECT, NCT04549025 / 2019-004953-96: Study of PD-1 Inhibitor JTX-4014 Alone and in Combination With Vopratelimab in Biomarker-selected Subjects With Metastatic NSCLC After One Prior Platinum-containing Regimen

Checkmark [VIRTUAL] Phase 2 study of PD-1 inhibitor JTX-4014 alone and in combination with vopratelimab, an ICOS agonist, in biomarker-selected subjects with metastatic NSCLC after one prior platinum-containing regimen (SELECT).
Checkmark Data from SELECT trial in combination with JTX-4014 for NSCLC at ASCO 2021
Recruiting
2
75
Europe, RoW
JTX-4014, Vopratelimab, JTX-2011
Jounce Therapeutics, Inc.
NSCLC
12/21
03/23
KEYNOTE-PN798, NCT03625323: Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC

Checkmark From TACTI-002 trial in combination with Keytruda for 2L HNSCC
Checkmark [VIRTUAL] Results from a phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected metastatic non-small cell lung carcinoma.
Checkmark [VIRTUAL] Results from a phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected metastatic second-line squamous head and neck carcinoma.
Checkmark From TACTI-002 trial in combination with Keytruda for NSCLC at ASCO 2021
Checkmark Initiated recruitment of additional 13 2L NSCLC patients for TACTI-002 study
More
Recruiting
2
183
Europe, US, RoW
Eftilagimod alpha, IMP321, Efti, Pembrolizumab, Keytruda, MK-3475
Immutep S.A.S., Merck Sharp & Dohme Corp.
NSCLC, HNSCC
05/22
05/23
Shevchuk, Viktoriia
NCT04469686 / 2019-003596-19: Phase 3 Study to Evaluate the Safety and Efficacy of Hydrocortisone Acetate Suppositories

Recruiting
3
618
Europe, US, RoW
Twice daily 90 mg hydrocortisone acetate suppository administered with Sephure applicator, Twice Daily - Active, Once daily 90 mg hydrocortisone acetate or placebo suppository administered with Sephure applicator, Once Daily - Active, Twice daily placebo suppository administered with Sephure applicator, Twice Daily - Placebo
Cristcot LLC, Cristcot HCA LLC
Ulcerative Proctitis
12/21
12/21
Dakhova, Yevheniia
NCT04469686 / 2019-003596-19: Phase 3 Study to Evaluate the Safety and Efficacy of Hydrocortisone Acetate Suppositories

Recruiting
3
618
Europe, US, RoW
Twice daily 90 mg hydrocortisone acetate suppository administered with Sephure applicator, Twice Daily - Active, Once daily 90 mg hydrocortisone acetate or placebo suppository administered with Sephure applicator, Once Daily - Active, Twice daily placebo suppository administered with Sephure applicator, Twice Daily - Placebo
Cristcot LLC, Cristcot HCA LLC
Ulcerative Proctitis
12/21
12/21
Pavlova, Olga
NCT04469686 / 2019-003596-19: Phase 3 Study to Evaluate the Safety and Efficacy of Hydrocortisone Acetate Suppositories

Recruiting
3
618
Europe, US, RoW
Twice daily 90 mg hydrocortisone acetate suppository administered with Sephure applicator, Twice Daily - Active, Once daily 90 mg hydrocortisone acetate or placebo suppository administered with Sephure applicator, Once Daily - Active, Twice daily placebo suppository administered with Sephure applicator, Twice Daily - Placebo
Cristcot LLC, Cristcot HCA LLC
Ulcerative Proctitis
12/21
12/21
NCT04588935: Prevention of Cardiovascular Diseases Caused by Complex Treatment of Patients With Primary Operated Breast Cancer

Recruiting
2
100
RoW
Bisoprolol; Perindopril;, Bisoprolol; Perindopril
State Institution "Republican Scientific and Practical Center" Cardiology, Belarus
Women With Breast Cancer
06/22
06/24

Download Options